Halozyme Therapeutics, Inc.

Halozyme Therapeutics develops proprietary enzymes and devices for various treatments. Products include Hylenex recombinant, rilpivirine, cabotegravir, ocrelizumab, XYOSTED, ATRS-1902, Herceptin, Mabthera SC, HYQVIA, DARZALEX, Epinephrine Injection, nivolumab+relatlimab, ANTI-TIM3, ARGX-117, atezolizumab, and others. The company provides treatments for breast cancer, chronic lymphocytic leukemia, primary immunodeficiency disorders, amyloidosis, smoldering myeloma, multiple myeloma, allergic reactions, solid tumors, and severe autoimmune diseases. Halozyme also offers products for adrenal crisis rescue and various other conditions. Founded in 1998, the company is headquartered in San Diego, California.

Overview

Sector

Biotechnology

Target Price

62.1 USD

Current Price

56.5 USD

Potential

10%

Strengths

Current Price to Earnings Ratio (16.03) is lower than the sector mean (91.15).
The company has high returns. ROIC (23.85%) is higher than the sector mean (6.02%).
EV/EBIT (15.03) is lower than the sector mean.
Price to free cash flow (15.20) is lower than the sector mean.
Strong EBITDA Margin of 62.32%.

Weaknesses

The company has high debt. Net Debt to EBITDA Ratio (2.42) is higher than the sector mean.

Key Financial Data

Indicator	Value
PER	15.7
EV/EBITDA	13.4
Price/Free Cash Flow'	14.8
ROIC	23.8%
Net Debt/EBITDA	2.4